InSilico at forefront of AI drug development

InSilico Medicine Cayman TopCo, an artificial intelligence drug discovery startup, said on Monday that it has secured a research and development deal worth up to $888 million with French pharmaceutical company Servier, capping a transformative week that saw the AI drug discoverer debut in Hong Kong's largest biotech listing of 2025.

The agreement adds global validation to InSilico's technology just days after it announced a separate R&D breakthrough with Chinese partner Zhejiang Hisun Pharmaceutical Co Ltd, reinforcing investor enthusiasm for artificial intelligence as a tool to slash drug development times.

Under the terms of the multi-year agreement announced on Monday, InSilico will be eligible to receive up to $32 million in upfront and near-term payments to deploy its proprietary Pharma. AI platform to discover novel treatments for difficult-to-target cancers. Including milestone payments, the total deal value could reach $888 million. Servier will share R&D costs and lead the subsequent clinical development, regulatory interactions and global commercialization of any resulting drugs. "This collaboration reflects our confidence in InSilico's internally developed and validated AI platform," said Christophe Thurieau, executive director of the Research Institute at Servier.